Abraxis BioScience (ABII)

ABRAXANE Market Data Highlights

According to recent IntrinsiQ data for June 2009, in all lines of metastatic breast cancer (MBC), ABRAXANE use represented 36.1 percent of the taxane market. On a rolling 12-month basis, the ABRAXANE share of total MBC taxane market was 31.4 percent.

ABRAXANE continues to be a leader in the taxane market in the second line + setting of the MBC market with a 44.6 percent market share in June 2009. In the third line + setting of the MBC market, ABRAXANE had a 49.7 percent share of the taxane market.

ABRAXANE Market Data Highlights

According to recent IntrinsiQ data for March 2009, in all lines of metastatic breast cancer (MBC), ABRAXANE use represented 34.8 percent of the taxane market. On a rolling 12-month basis, ABRAXANE taxane share of total MBC increased to 32 percent from 29.1 percent since March 2008.

ABRAXANE continues to be the taxane market leader in the second line + setting of the MBC market with a 42.6 percent market share in March 2009. In the third line + setting of the MBC market, ABRAXANE had a 46.4 percent share of the taxane market.

ABRAXANE Market Data Highlights

According to recent IntrinsiQ data for December 2008, in metastatic breast cancer (MBC), ABRAXANE closed 2008 with continued taxane market leadership, capturing the highest all time share of 37.7 percent in December 2008.

ABRAXANE continues to be the taxane of choice in the second line setting. In the second line + setting of the MBC taxane market, ABRAXANE remains the leader with a share of 49.6 percent. In the third line + setting of the MBC market in December 2008, ABRAXANE has maintained the lion share of the taxane market with a 56.7 percent share. Although not approved by the FDA in first-line MBC, ABRAXANE share of the taxane market in first line MBC increased 4.8 percent in December 2008 to a share of 22.7 percent. The total number of patients that have been on ABRAXANE throughout all indications has increased by 14.1 percent since January 2008.

ABRAXANE Market Data Highlights

According to recent IntrinsiQ data for September 2008, in metastatic breast cancer (MBC), ABRAXANE usage increased to 36 percent of the overall taxane market, compared with 33 percent in June 2008. ABRAXANE share of the taxane market in 2nd line MBC continues to increase and achieved an all time high of 41.5 percent, representing a 4.5 percent increase since June 2008.